Rafael Holdings Inc - Ordinary Shares - Class B Stock News

Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol® Cyclo™ Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol® Cyclo™

Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need

NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Manitex International, Inc. (NASDAQ:MNTX)'s sale to Tadano Ltd. for $5.80 per share in cash.

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025

NEWARK, N.J. & GAINESVILLE, Fla.--(BUSINESS WIRE)--Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares ...